Page last updated: 2024-11-03

probucol and Elevated Cholesterol

probucol has been researched along with Elevated Cholesterol in 176 studies

Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.

Research Excerpts

ExcerptRelevanceReference
"This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia."9.19Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014)
"To clarify whether probucol and statins suppress oxidative stress in diabetic patients, we studied the effects of probucol and the statin atorvastatin on urinary 8-hydroxy-2'deoxyguanosine (8-OHdG) levels in diabetics with hypercholesterolemia."9.12Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. ( Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006)
"The changes in lipoproteins induced by lovastatin (L) and probucol (P) were compared in patients with primary hypercholesterolemia."9.07[Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study]. ( Forti, N; Ramires, JA, 1991)
"A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia."9.06A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990)
"In order to compare the effects of lovastatin and probucol on lipoprotein profiles, we treated 32 familial hypercholesterolemia (FH) heterozygotes and 26 patients with non-familial hypercholesterolemia for 14 weeks with either probucol (1 g/d) or lovastatin (40-80 mg/d) in a randomized double-blind study."9.06Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. ( Helve, E; Tikkanen, MJ, 1988)
"Probucol (1 g per day) was administered in a double-blind crossover trial to 16 patients with familial hypercholesterolemia who had previously been tested for their response to clofibrate."9.05Usefulness of probucol in treating primary hypercholesterolemia. ( Davignon, J; DuBreuil-Quidoz, S; Enjalbert, M; LeLorier, J; Lussier-Cacan, S, 1980)
"The effect of Probucol on serum lipids, lipoproteins and the apoproteins A1, A2 and B was studied in 27 patients with primary hypercholesterolemia."9.05Probucol in hypercholesterolemia. A double blind study. ( Keller, M; Mordasini, R; Riesen, WF, 1980)
"The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits."7.81Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015)
"This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima."7.79Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. ( Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2013)
" In the present study, we investigated the beneficial effects of combinatorial therapy with probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia."7.77Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. ( Bae, SS; Choi, BT; Hong, KW; Kim, JH; Kim, YD; Park, KP; Park, SH; Shin, HK, 2011)
" We hypothesized that pitavastatin restores vascular function by modulating oxidative stress through the activation of Cu/ZnSOD and PPAR-gamma in hypercholesterolemia."7.73Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. ( Fukai, T; Itoh, S; Kawahara, S; Matsuzaki, M; Tanaka, M; Umeji, K; Umemoto, S, 2006)
"We report a patient who experienced a reversible prolongation of the QT interval and episodes of syncope while receiving probucol."7.69Probucol-induced QT prolongation and syncope. ( Ito, M; Ohtsuka, E; Oribe, K; Oribe, M; Seita, M; Tamura, M; Ueki, Y, 1994)
"In nonhuman primates (Macaca nemestrina) treated with the antioxidant probucol during diet-induced hypercholesterolemia, intimal lesion area in the thoracic aorta was decreased, with increased resistance of plasma LDL to oxidation."7.69Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. ( Chait, A; Chang, MY; Raines, EW; Ross, R; Sasahara, M, 1995)
"A time-dependent change in the cholesterol-lowering effect of probucol has been evaluated in 20 subjects with elevated cholesterol."7.68Time-dependent change in the effect of probucol in subjects with elevated cholesterol. ( Ebihara, A; Fujimura, A; Ohashi, K, 1992)
"Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol."7.67Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988)
"Carotid atherosclerosis is a strong, independent predictor of morbidity and mortality in patients with coronary heart disease (CHD)."6.70Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). ( Hayashi, J; Kashiwagi, S; Kinukawa, N; Koyanagi, S; Maeda, N; Sawayama, Y; Shimizu, C; Tatsukawa, M, 2002)
"Post-transplant hypercholesterolemia is featured with abnormalities in very low-density lipoprotein (VLDL) metabolism."6.69Effect of probucol on hypercholesterolemia in renal transplant patients. ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Nakamura, M; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1999)
"Both simvastatin doses were significantly more effective than probucol in improving the plasma lipid profile."6.66Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). ( Alexander, S; Cook, TJ; Mantell, G; Pietro, DA; Staggers, JE, 1989)
"Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol."6.66Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia. ( Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M, 1986)
"Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels."6.36Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982)
" Recently, a new microemulsion formulation of CyA(Neoral) has been developed and used preferably because of a more stable bioavailability than an oily formulation(Sandimmun)."5.31[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]. ( Inui, K; Muso, E; Ono, T; Wakasugi, H; Yoshimoto, M, 2002)
"Treatment with probucol (500 mg/day) or pravastatin (10 mg/day) reduced mean plasma total cholesterol concentrations by 24% (p < 0."5.29Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia. ( Ishikawa, T; Kagami, A; Manabe, M; Mochizuki, K; Moriguchi, EH; Nagano, M; Sakamoto, T; Tada, N, 1993)
"Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos."5.29Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? ( Carew, TE; Chait, A; Raines, EW; Ross, R; Sasahara, M; Steinberg, D; Wahl, PW, 1994)
"Probucol was ineffective in altering this cholesterol-induced increase in enzyme activity except in Group III where it increased the activity of GSH-Px."5.29Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. ( Kalra, J; Mantha, SV; Prasad, K, 1996)
"The lovastatin-alone regimen was well tolerated, whereas addition of colestipol caused subjective side effects in many patients."5.28Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. ( Helve, E; Karjalainen, K; Ojala, JP; Tarkkanen, A; Tikkanen, MJ, 1990)
"Probucol is a lipid-lowering drug with a well-known antioxidant action."5.28Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. ( Bargalló, MT; Casals, I; LaVille, A; Masana, L; Plana, N; Solà, R, 1991)
"This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia."5.19Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014)
"To clarify whether probucol and statins suppress oxidative stress in diabetic patients, we studied the effects of probucol and the statin atorvastatin on urinary 8-hydroxy-2'deoxyguanosine (8-OHdG) levels in diabetics with hypercholesterolemia."5.12Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. ( Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006)
"The changes in lipoproteins induced by lovastatin (L) and probucol (P) were compared in patients with primary hypercholesterolemia."5.07[Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study]. ( Forti, N; Ramires, JA, 1991)
"In order to compare the effects of lovastatin and probucol on lipoprotein profiles, we treated 32 familial hypercholesterolemia (FH) heterozygotes and 26 patients with non-familial hypercholesterolemia for 14 weeks with either probucol (1 g/d) or lovastatin (40-80 mg/d) in a randomized double-blind study."5.06Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. ( Helve, E; Tikkanen, MJ, 1988)
"A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia."5.06A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990)
"A variety of double-blind studies have compared the efficacy of hydroxymethylglutaryl coenzyme A reductase inhibitors (lovastatin and simvastatin) with that of control agents (cholestyramine, fibrates and probucol) in patients with type IIA or IIB primary hypercholesterolemia."5.06Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia. ( Shapiro, DR; Walker, JF, 1990)
"The effect of Probucol on serum lipids, lipoproteins and the apoproteins A1, A2 and B was studied in 27 patients with primary hypercholesterolemia."5.05Probucol in hypercholesterolemia. A double blind study. ( Keller, M; Mordasini, R; Riesen, WF, 1980)
"Probucol (1 g per day) was administered in a double-blind crossover trial to 16 patients with familial hypercholesterolemia who had previously been tested for their response to clofibrate."5.05Usefulness of probucol in treating primary hypercholesterolemia. ( Davignon, J; DuBreuil-Quidoz, S; Enjalbert, M; LeLorier, J; Lussier-Cacan, S, 1980)
"Administration of probucol to 23 patients with familial xanthomatotic hypercholesterolaemia reduced the serum cholesterol level during the 9-month study by 9%, while in 15 patients with less severe hypercholesterolaemia the decrease was on an average 15%."5.04Treatment of severe and mild hypercholesterolaemia with probucol and neomycin. ( Miettinen, TA; Toivonen, I, 1975)
"We have shown that probucol-induced HDL deficiency impairs the ability of established lesions to regress in response to reversal of the genetic hypercholesterolemia in Apoe knockout mice."3.88HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution. ( Hoekstra, M; Lendvai, Z; van der Sluis, RJ; Van Eck, M; Verwilligen, RAF; Wever, R, 2018)
"The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits."3.81Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015)
"This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima."3.79Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. ( Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2013)
" In the present study, we investigated the beneficial effects of combinatorial therapy with probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia."3.77Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. ( Bae, SS; Choi, BT; Hong, KW; Kim, JH; Kim, YD; Park, KP; Park, SH; Shin, HK, 2011)
" We hypothesized that pitavastatin restores vascular function by modulating oxidative stress through the activation of Cu/ZnSOD and PPAR-gamma in hypercholesterolemia."3.73Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. ( Fukai, T; Itoh, S; Kawahara, S; Matsuzaki, M; Tanaka, M; Umeji, K; Umemoto, S, 2006)
"Inhibitors of the key enzyme of cholesterol biosynthesis beta-hydroxy-beta-methylglutaryl-coenzyme A reductase (statins) decrease cholesterol content in atherogenic low-density lipoproteins in patients with coronary heart disease and hypercholesterolemia, but inhibited biosynthesis of ubiquinone Q10 protecting low-density lipoproteins from free radical oxidation."3.71Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein pe ( Belenkov, YN; Konovalova, GG; Kotkina, TI; Kukharchuk, VV; Lankin, VZ; Medvedeva, NV; Tikhaze, AK; Tutunov, VS, 2002)
" To clarify the mechanisms underlying vascular dysfunction and oxidative stress in hypercholesterolemia, we compared the effects of antioxidant probucol with those of pravastatin on aortic stiffness, phenotypic modulation, oxidative stress, and NAD(P)H oxidase essential subunit p22(phox) expression in aortic medial SM cells of cholesterol-fed rabbits by using color image analysis of immunostained sections."3.71Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. ( Aoyagi, S; Fujii, T; Hiromoto, M; Itoh, S; Matsuzaki, M; Tanaka, M; Toma, Y; Tomochika, Y; Umemoto, S, 2002)
"The therapeutic effect of probucol on hypercholesterolemia in cyclosporine A (CyA)-treated renal transplant patients was prospectively studied."3.70Effect of probucol on serum lipoprotein and apoprotein profiles in renal transplant patients. ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Kumano, K; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1998)
"A 62-year-old man with old myocardial infarction and familial hypercholesterolemia was treated by both probucol and low-density lipoprotein (LDL) apheresis."3.70Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography. ( Arakawa, K; Jimi, S; Naito, S; Nii, T; Okabe, M; Saku, K; Shirai, K; Takeda, Y, 1998)
"In nonhuman primates (Macaca nemestrina) treated with the antioxidant probucol during diet-induced hypercholesterolemia, intimal lesion area in the thoracic aorta was decreased, with increased resistance of plasma LDL to oxidation."3.69Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. ( Chait, A; Chang, MY; Raines, EW; Ross, R; Sasahara, M, 1995)
"We report a patient who experienced a reversible prolongation of the QT interval and episodes of syncope while receiving probucol."3.69Probucol-induced QT prolongation and syncope. ( Ito, M; Ohtsuka, E; Oribe, K; Oribe, M; Seita, M; Tamura, M; Ueki, Y, 1994)
" In the present study we examined whether lipid-soluble antioxidants, probucol and vitamin E, could inhibit renal injury in rats with chronic puromycin aminonucleoside (PA) nephrosis and dietary hypercholesterolemia by protecting lipoproteins from oxidation."3.69Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. ( Chung, HK; Jeong, JY; Kim, BC; Kim, YS; Lee, HS; Zhang, YZ, 1997)
"Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics."3.69Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. ( Baldassarre, D; Brusoni, B; Franceschini, G; Peruzzotti, G; Sirtori, CR, 1997)
"A time-dependent change in the cholesterol-lowering effect of probucol has been evaluated in 20 subjects with elevated cholesterol."3.68Time-dependent change in the effect of probucol in subjects with elevated cholesterol. ( Ebihara, A; Fujimura, A; Ohashi, K, 1992)
"An assessment has been made regarding the changes of the particles of lipoprotein A-I without A-II (Lp A-I) and lipoprotein A-I with A-II (LpA-I/A-II) which correspond to HDL subfraction isolated by the use of anti-apo A-I and A-II antibody affinity columns in order to quantitatively and qualitatively investigate the change of HDL caused by administration of probucol and pravastatin which are therapeutic drugs for hypercholesterolemia."3.68[Separation of high density lipoprotein (HDL) using anti-apo A-I, apo A-II immuno-affinity chromatography to evaluate the effects of probucol]. ( Hino, K; Ishikawa, T; Kagami, A; Manabe, M; Mochizuki, K; Sakamoto, T; Satoh, N; Tada, N, 1991)
"Eight patients with primary hypercholesterolemia were treated with probucol for 17 weeks."3.68Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism. ( Albers, HW; Barnhart, RL; Chi, EM; Combs, KA; Harmony, JA; Jackson, RL; Lamkin, G; Stein, EA; Wetterau, JR, 1992)
"Despite probucol's capacity to induce regression of tendinous xanthomata and reduce whole plasma and LDL cholesterol (LDL-C) in patients with hypercholesterolemia, its therapeutic use in the United States has been limited because of concern about its HDL-lowering effects."3.68Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer. ( Bagdade, JD; Kaufman, D; Ritter, MC; Subbaiah, PV, 1990)
"The QT, QTc, QS2 intervals, pre-ejection period-left ventricular ejection time ratios and serum lipoprotein levels were measured in 8 patients with primary hypercholesterolemia before and after a 3-month therapy with probucol, 1 g/day."3.67The effects of probucol on QT/QS2 relation and systolic time intervals. ( Fenyvesi, T; László, Z; Littmann, L; Romics, L, 1988)
"Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol."3.67Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988)
"Ten men with hypercholesterolemia were treated sequentially with a fat-modified diet, a diet plus probucol (1 Gm/day), and a diet plus probucol plus cholestyramine (16 Gm/day)."3.66Synergistic effects of probucol and cholestyramine to lower serum cholesterol. ( Boyden, TW; Totman, L, 1981)
"Carotid atherosclerosis is a strong, independent predictor of morbidity and mortality in patients with coronary heart disease (CHD)."2.70Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). ( Hayashi, J; Kashiwagi, S; Kinukawa, N; Koyanagi, S; Maeda, N; Sawayama, Y; Shimizu, C; Tatsukawa, M, 2002)
"Post-transplant hypercholesterolemia is featured with abnormalities in very low-density lipoprotein (VLDL) metabolism."2.69Effect of probucol on hypercholesterolemia in renal transplant patients. ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Nakamura, M; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1999)
"Bezafibrate was administered at either 200 mg."2.68High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate. ( Arakawa, K; Bai, H; Hirata, K; Jimi, S; Liu, R; Saku, K; Sasaki, N; Zhang, B, 1995)
"Probucol was not found to effect progression regression of femoral atherosclerosis significantly as assessed by quantitative arteriography."2.68The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. ( Elinder, LS; Holme, I; Johansson, J; Mölgaard, J; Nilsson, J; Nilsson, S; Olsson, AG; Regnström, J; Walldius, G, 1996)
"Both simvastatin doses were significantly more effective than probucol in improving the plasma lipid profile."2.66Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). ( Alexander, S; Cook, TJ; Mantell, G; Pietro, DA; Staggers, JE, 1989)
"Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol."2.66Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia. ( Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M, 1986)
" The daily dosage of probucol was 1 g divided into two 500 mg doses."2.65[A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)]. ( Cerimelle, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1980)
"Monitored clinical studies conducted in 1133 patients, involving 3928 patient years of experience with probucol, have shown that it is an effective cholesterol lowering agent and is well tolerated during long term administration (some patients treated for as long as nine years)."2.65Safety and effectiveness of probucol as a cholesterol lowering agent. ( Cerimele, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1982)
" In 32 patients with Type II HL and 12 with Type IIB HL, statistically significant reduction in mean serum cholesterol levels occurred within two weeks and persisted throughout two years of therapy at constant dosage (500 mg."2.64Effect of probucol in hyperlipidemic patients during two years of administration. ( Parsons, WB, 1978)
" Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients."2.64Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia. ( Mason, DT; Price, J; Salel, AF; Sodhi, HS; Zelis, R, 1976)
"Niacin was the most efficient agent for reducing low-density lipoprotein cholesterol levels, having an average cost over 5 years of $139 per percent reduction in low-density lipoprotein cholesterol level."2.38Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. ( Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK, 1990)
"Probucol is a lipid-regulating agent structurally dissimilar to other known agents, with a unique pharmacodynamic and clinical profile."2.38Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. ( Brogden, RN; Buckley, MM; Goa, KL; Price, AH, 1989)
"Probucol is a widely used serum-cholesterol lowering drug."2.37Mode of hypocholesterolemic action of probucol in animals and man. ( Beynen, AC, 1987)
"The surgical treatment of hypercholesterolemia and the treatment of homozygous and other forms of hypercholesterolemia are also detailed."2.36Treatment of hypercholesterolemia. ( Kane, JP; Malloy, MJ, 1982)
"Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels."2.36Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982)
"Probucol has anti-oxidant properties as well as cholesterol-lowering effects and may affect soluble thrombomodulin (sTM)."1.35Effect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits. ( Hong, SC; Liu, Q; Wu, ZH; Zhao, SP, 2008)
"Probucol is known to be a potent hypolipidemic drug to regress xanthoma formation and carotid atherosclerosis in conjunction with a marked reduction in HDL-cholesterol levels."1.34Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits. ( Hong, SC; Wu, ZH; Zhao, SP, 2007)
" Recently, a new microemulsion formulation of CyA(Neoral) has been developed and used preferably because of a more stable bioavailability than an oily formulation(Sandimmun)."1.31[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]. ( Inui, K; Muso, E; Ono, T; Wakasugi, H; Yoshimoto, M, 2002)
"We have established a reproducible stenosis model in hypercholesterolemic hamsters, and the process of arterial stenosis by thrombus or neointima was studied and compared with that in normal hamsters."1.31Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. ( Abe, A; Kozawa, O; Matsuno, H; Niwa, M; Takiguchi, Y; Uematsu, T, 2001)
" Calculated bioavailability following oral administration of cyclosporin A decreased by 33% with the treatment of probucol."1.30Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats. ( Fujimura, A; Sakamoto, K; Sugimoto, K, 1997)
"Probucol, a drug commonly employed for treatment of hypercholesterolemia, has antioxidant properties and inhibits oxidation of low density lipoproteins in vitro."1.30Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits. ( Fukai, T; Harrison, DG; Inoue, N; Nishida, K; Ohara, Y, 1998)
" Silybin was not so effective as silymarin suggesting that either other constituent(s) of silymarin may be responsible for its anticholesterolemic effect or the bioavailability of silybin alone might be lower than that of silybin as a compound of silymarin."1.30Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. ( Krecman, V; Simánek, V; Skottová, N; Ulrichová, J; Walterová, D, 1998)
"A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction."1.30Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997)
"Probucol treatment results in an increase in plasma concentrations of cholesteryl ester transfer protein (CETP) which may account, in part, for the effects of this agent on plasma concentrations of HDL cholesterol."1.29Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. ( Huerta, P; Marcel, YL; McPherson, R; Nancoo, D; Quinet, EM; Tall, AR, 1993)
"Treatment with probucol (500 mg/day) or pravastatin (10 mg/day) reduced mean plasma total cholesterol concentrations by 24% (p < 0."1.29Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia. ( Ishikawa, T; Kagami, A; Manabe, M; Mochizuki, K; Moriguchi, EH; Nagano, M; Sakamoto, T; Tada, N, 1993)
"Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos."1.29Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? ( Carew, TE; Chait, A; Raines, EW; Ross, R; Sasahara, M; Steinberg, D; Wahl, PW, 1994)
"Probucol was ineffective in altering this cholesterol-induced increase in enzyme activity except in Group III where it increased the activity of GSH-Px."1.29Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. ( Kalra, J; Mantha, SV; Prasad, K, 1996)
"The lovastatin-alone regimen was well tolerated, whereas addition of colestipol caused subjective side effects in many patients."1.28Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. ( Helve, E; Karjalainen, K; Ojala, JP; Tarkkanen, A; Tikkanen, MJ, 1990)
"Probucol treatment in hypercholesterolemic patients promotes the transfer of cholesteryl esters from high-density-lipoproteins (HDL) to lower-density lipoproteins."1.28In vitro activity of probucol on cholesteryl ester transport. ( Chiesa, G; Franceschini, G; Sirtori, CR, 1990)
"There are indications that treatment of hypercholesterolemia by means of drugs reduce risk of atherosclerosis in patients with increased concentrations of atherogenic lipoproteins."1.28[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]. ( Blomhoff, JP; Ose, L; Torsvik, H, 1989)
"Probucol is a lipid-lowering drug with a well-known antioxidant action."1.28Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. ( Bargalló, MT; Casals, I; LaVille, A; Masana, L; Plana, N; Solà, R, 1991)
"Probucol is a drug that lowers both LDL and HDL cholesterol levels."1.27Lipoprotein fractions and receptors: a role for probucol? ( Bilheimer, DW, 1986)
" These findings suggest that there is an optimum dosage of probucol to lower LDL + VLDL cholesterol and the atherogenic index, and that the actual optimum dosage for the beneficial effect depends on blood lipid levels or types of hyperlipidemia."1.26Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice. ( Abiko, Y; Nakayasu, T; Tawara, K; Tomikawa, M, 1981)
" Repeated administration of probucol to healthy volunteers showed good correlation between dosage and blood levels."1.26[Plasma levels of probucol in man after single and repeated oral doses (author's transl)]. ( Heeg, JF; Tachizawa, H, 1980)
"Probucol seems to be a non hepatotoxic drug and induces a decrease of lithogenic index of bile."1.26[Probucol: mechanism of action (author's transl)]. ( Infante, R, 1980)

Research

Studies (176)

TimeframeStudies, this research(%)All Research%
pre-199083 (47.16)18.7374
1990's64 (36.36)18.2507
2000's19 (10.80)29.6817
2010's10 (5.68)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
van der Sluis, RJ1
Verwilligen, RAF1
Lendvai, Z1
Wever, R1
Hoekstra, M1
Van Eck, M1
Niimi, M1
Keyamura, Y1
Nozako, M1
Koyama, T1
Kohashi, M1
Yasufuku, R1
Yoshikawa, T1
Fan, J3
Takase, B1
Nagata, M1
Hattori, H1
Tanaka, Y1
Ishihara, M1
Kim, JH2
Hong, KW2
Bae, SS2
Shin, YI1
Choi, BT2
Shin, HK2
Wang, Y2
Bai, L2
Lin, Y2
Guan, H2
Zhu, N2
Chen, Y2
Li, Y2
Gao, S2
Zhao, S2
Liu, E2
Sun, L1
Yakushiji, E1
Ayaori, M1
Nishida, T1
Shiotani, K1
Takiguchi, S1
Nakaya, K1
Uto-Kondo, H1
Ogura, M1
Sasaki, M1
Yogo, M1
Komatsu, T1
Lu, R1
Yokoyama, S1
Ikewaki, K1
Yamashita, S4
Bujo, H1
Arai, H1
Harada-Shiba, M1
Matsui, S1
Fukushima, M1
Saito, Y1
Kita, T3
Matsuzawa, Y3
Park, SH1
Kim, YD1
Park, KP1
Fang, L1
Green, SR1
Baek, JS1
Lee, SH1
Ellett, F1
Deer, E1
Lieschke, GJ1
Witztum, JL3
Tsimikas, S1
Miller, YI1
Moreira, EL1
de Oliveira, J1
Dutra, MF1
Santos, DB1
Gonçalves, CA1
Goldfeder, EM1
de Bem, AF1
Prediger, RD1
Aschner, M1
Farina, M1
Nagai, Y2
Yanagi, K1
Takemura, K1
Lankin, VZ2
Tikhaze, AK1
Konovalova, GG1
Tutunov, VS1
Medvedeva, NV1
Kotkina, TI1
Kukharchuk, VV1
Belenkov, YN1
Wakasugi, H1
Yoshimoto, M1
Ono, T1
Muso, E1
Inui, K1
Nakao, A1
Nosaka, K1
Imaki, H1
Noiri, E1
Toda, A1
Doi, K1
Suzuki, Y1
Fujita, T1
Kimura, S1
Hong, SC3
Zhao, SP3
Wu, ZH3
Endo, K1
Miyashita, Y1
Sasaki, H1
Ebisuno, M1
Ohira, M1
Saiki, A1
Koide, N1
Oyama, T1
Takeyoshi, M1
Shirai, K2
Sawayama, Y2
Maeda, S2
Ohnishi, H1
Okada, K1
Hayashi, J2
Xu, G1
Li, XS1
Huang, WQ1
Huang, H1
Umeji, K1
Umemoto, S2
Itoh, S2
Tanaka, M2
Kawahara, S1
Fukai, T2
Matsuzaki, M2
Liu, Q1
Bateson, MC2
Miettinen, TA5
Huttunen, JK2
Strandberg, T2
Naukkarinen, V2
Mattila, S2
Kumlin, T2
Troendle, G1
Guerigian, J1
Sobel, S1
Johnson, M1
Donatelli, L2
Dujovne, CA3
Chernoff, SB2
Krehbiel, P2
Jackson, B1
DeCoursey, S1
Taylor, H1
Kesäniemi, YA1
Grundy, SM2
Santos, Rde O1
Moriguchi, Y1
McCaughan, D2
Tomikawa, M1
Nakayasu, T1
Tawara, K1
Abiko, Y1
Quintão, EC1
Maranhão, RC1
Tedeschi, RE2
Martz, BL3
Taylor, HA2
Cerimelle, BJ1
Glueck, CJ1
Kane, JP2
Malloy, MJ1
Cerimele, BJ1
Mordasini, R2
Riesen, W1
Oster, P1
Riva, G1
Kuusi, T1
Davignon, J2
Lussier-Cacan, S2
Dubreuil-Quidoz, S2
LeLorier, J2
Opplt, JJ1
Chick, LL1
Opplt, MA1
Magill, P1
Whiting, C1
Hammett, F1
Glick, I1
Miller, NE2
Lewis, B2
Schonfeld, G1
Witztum, J1
Basich, P1
Cortese, C1
Marenah, CB1
Pasquali, R1
Melchionda, N1
Parenti, M1
Cavazzini, MG1
Biso, P1
Baraldi, G1
Sorrenti, G1
De Benedittis, G1
Labò, G1
Boyden, TW1
Totman, L1
Herdová, J1
Zapletalová, J1
Fiabane, AM1
Clarke, A1
Bouchier, IA1
Mishkel, MA1
Crowther, SM1
Duarte, GM1
Lavall, M1
da Cunha, GP1
da Cunha, CL1
Riesen, WF1
Keller, M1
Infante, R1
Heeg, JF1
Tachizawa, H1
Roach, L1
Botha, A1
Joffe, BI1
Baker, SG1
Shires, R1
Seftel, HC1
Enjalbert, M1
Chang, MY1
Sasahara, M2
Chait, A2
Raines, EW2
Ross, R2
Saku, K4
Zhang, B3
Jimi, S2
Bai, H2
Hirata, K3
Sasaki, N2
Liu, R3
Arakawa, K4
Yamamoto, K2
Fukuda, N2
Shiroi, S2
Shiotsuki, Y2
Nagata, Y2
Tani, T2
Sakai, T2
Johansson, J6
Olsson, AG6
Bergstrand, L2
Elinder, LS3
Nilsson, S5
Erikson, U4
Mölgaard, J4
Holme, I3
Walldius, G7
Hådell, K3
Mølgaard, J1
Parker, RA1
Sabrah, T1
Cap, M1
Gill, BT1
Anderson, TJ1
Meredith, IT1
Yeung, AC1
Frei, B1
Selwyn, AP1
Ganz, P1
Hattori, M1
Ito, K1
Kawaguchi, H1
Yamaguchi, Y2
Kaijser, L2
Lassvik, C2
Tamura, M1
Ueki, Y1
Ohtsuka, E1
Oribe, M1
Seita, M1
Oribe, K1
Ito, M1
Carew, TE1
Steinberg, D2
Wahl, PW1
Kitagawa, S1
Imaizumi, N1
Kunitomo, M1
Fujiwara, M1
Okura, Y1
Ohya, Y1
Kumamoto, K1
Abe, I1
Tsubota, Y1
Fujishima, M1
Regnström, J3
Nilsson, J3
Schäfer-Elinder, L1
Moelgaard, J1
Carlson, LA3
Kagami, A2
Ishikawa, T2
Tada, N2
Sakamoto, T2
Mochizuki, K2
Nagano, M1
Moriguchi, EH1
Manabe, M2
Ikeda, T1
Quinet, EM1
Huerta, P1
Nancoo, D1
Tall, AR1
Marcel, YL1
McPherson, R2
Moroe, K1
Mantha, SV1
Kalra, J1
Prasad, K1
Del Rio, M1
Chulia, T1
Ruiz, E1
Tejerina, T1
Sugimoto, K1
Sakamoto, K1
Fujimura, A2
Lee, HS1
Jeong, JY1
Kim, BC1
Kim, YS1
Zhang, YZ1
Chung, HK1
Kesten, S1
Mayne, L1
Scavuzzo, M1
Maurer, J1
Jorge, PA1
Baldassarre, D1
Franceschini, G2
Peruzzotti, G1
Brusoni, B1
Sirtori, CR2
Okubo, M2
Horii, A2
Kamata, K2
Takeuchi, Y2
Tsukamoto, Y2
Kobayashi, N2
Sato, K2
Kumano, K1
Endo, T2
Krecman, V1
Skottová, N1
Walterová, D1
Ulrichová, J1
Simánek, V1
Inoue, N1
Ohara, Y1
Harrison, DG1
Nishida, K1
Takeda, Y1
Okabe, M1
Nii, T1
Naito, S1
Miida, T1
Yamaguchi, T1
Tsuda, T1
Okada, M1
Donetti, E1
Soma, MR1
Barberi, L1
Paoletti, R1
Fumagalli, R1
Roma, P1
Catapano, AL1
Harada, N1
Kashiwagi, A1
Nishio, Y1
Kikkawa, R1
Kodama, N1
Otani, H1
Yamada, Y1
Mune, M1
Yukawa, S1
Nakamura, M1
Fruebis, J1
Silvestre, M1
Shelton, D1
Napoli, C1
Palinski, W1
Pfuetze, KD1
Chin-Dusting, JP1
Shaw, JA1
Kimura, Y1
Uchiyama, S1
Matsuno, H1
Kozawa, O1
Niwa, M1
Abe, A2
Takiguchi, Y1
Uematsu, T1
Schwenke, DC1
Behr, SR1
Shimizu, C1
Maeda, N1
Tatsukawa, M1
Kinukawa, N1
Koyanagi, S1
Kashiwagi, S1
Hiromoto, M1
Toma, Y1
Tomochika, Y1
Aoyagi, S1
Fujii, T1
Salel, AF1
Zelis, R1
Sodhi, HS1
Price, J1
Mason, DT1
Murphy, BF1
Toivonen, I2
Heel, RC1
Brogden, RN2
Speight, TM1
Avery, GS1
Parsons, WB1
Forti, N2
Diament, J1
Giannini, SD1
Rapado, A1
Castrillo, JM1
Díaz-Curiel, M1
Nash, DT2
Kisanuki, A1
Asada, Y1
Hatakeyama, K1
Hayashi, T1
Sumiyoshi, A1
Bocan, TM1
Mueller, SB1
Brown, EQ1
Uhlendorf, PD1
Mazur, MJ1
Newton, RS1
Ohashi, K1
Ebihara, A1
Baumstark, MW2
Arístegui, R1
Zöller, T1
Frey, I2
Berg, A2
Keul, J2
Reaven, PD1
Parthasarathy, S2
Beltz, WF1
Florkowski, CM1
Cramb, R1
Wetterau, JR1
Combs, KA1
Albers, HW1
Lamkin, G1
Stein, EA1
Barnhart, RL1
Chi, EM1
Jackson, RL1
Harmony, JA1
Hino, K1
Satoh, N1
Ramires, JA1
Liu, K1
Lupanov, VP1
Liakishev, AA1
Revenko, VM1
Masana, L1
Bargalló, MT1
Plana, N1
LaVille, A1
Casals, I1
Solà, R1
Marcel, Y1
Halle, M1
Schulman, KA1
Kinosian, B1
Jacobson, TA1
Glick, H1
Willian, MK1
Koffer, H1
Eisenberg, JM1
Walker, JF1
Shapiro, DR1
Nagano, Y1
Bagdade, JD1
Kaufman, D1
Ritter, MC1
Subbaiah, PV1
Ojala, JP1
Helve, E3
Karjalainen, K1
Tarkkanen, A1
Tikkanen, MJ4
Chiesa, G1
Howard, PA1
Okuno, M1
Noma, A1
Ishii, K1
Pietro, DA1
Alexander, S1
Mantell, G1
Staggers, JE1
Cook, TJ1
Buckley, MM1
Goa, KL1
Price, AH1
Ose, L1
Blomhoff, JP1
Torsvik, H1
Shankar, R1
Sallis, JD1
Stanton, H1
Thomson, R1
Yoshino, G1
Kazumi, T1
Uenoyama, R1
Inui, A1
Kasama, T1
Iwatani, I1
Iwai, M1
Yokono, K1
Otsuki, M1
Baba, S1
Strandberg, TE1
Vanhanen, H1
Hunninghake, DB1
Schwartz, CJ1
Stenport, G1
Fonteles, MC1
Costa e Forti, A1
de Freitas, MT1
Nikkilä, EA2
Cohen, L1
Morgan, J1
Funahashi, T1
Yamamoto, A1
Tarui, S1
Romics, L1
Littmann, L1
László, Z1
Fenyvesi, T1
Havel, RJ1
Valeri, A1
Gelfand, J1
Blum, C1
Appel, GB1
Beynen, AC2
Bilheimer, DW1
DiPalma, JR1
Eder, HA1
Sommariva, D1
Bonfiglioli, D1
Tirrito, M1
Pogliaghi, I1
Branchi, A1
Cabrini, E1
Young, SG1
Pittman, RC1
Polachek, AA1
Katz, HM1
Sack, J1
Selig, J1
Littman, ML1
Harris, RS1
Gilmore, HR1
Bricker, LA1
Kiem, IM1
Rubin, E1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641]Phase 4342 participants (Actual)Interventional2011-03-31Completed
[NCT00005681]0 participants Observational1989-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

25 reviews available for probucol and Elevated Cholesterol

ArticleYear
[Treatment of high blood cholesterol in patients with coronary heart disease].
    Nihon rinsho. Japanese journal of clinical medicine, 1994, Volume: 52 Suppl, Issue:Pt 1

    Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethy

1994
[Treatment of high blood cholesterol in patients with coronary heart disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4

    Topics: Anion Exchange Resins; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Di

2003
[Pharmacology of probucol. I].
    La Clinica terapeutica, 1984, Mar-15, Volume: 108, Issue:5

    Topics: Adult; Aged; Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Cholesterol; Clofibra

1984
[Pharmacology of probucol. II].
    La Clinica terapeutica, 1984, Mar-31, Volume: 108, Issue:6

    Topics: Animals; Cholesterol; Dogs; Drug Evaluation; Female; Heart; Heart Rate; Humans; Hypercholesterolemia

1984
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
    Circulation, 1984, Volume: 69, Issue:5

    Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl

1984
Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
    Annals of internal medicine, 1982, Volume: 96, Issue:4

    Topics: Arteriosclerosis; Cholesterol; Colestipol; Drug Therapy, Combination; Humans; Hypercholesterolemia;

1982
Treatment of hypercholesterolemia.
    The Medical clinics of North America, 1982, Volume: 66, Issue:2

    Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hyper

1982
[Endothelium, lipids and atherosclerosis].
    Arquivos brasileiros de cardiologia, 1997, Volume: 68, Issue:2

    Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Endocytosis; Endothelium, Vascular; Foam Cells;

1997
Probucol.
    Current atherosclerosis reports, 2000, Volume: 2, Issue:1

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular

2000
Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3

    Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA

2001
[Hyperlipidemia and cerebrovascular disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 2

    Topics: Anticholesteremic Agents; Apolipoproteins; Cerebral Infarction; Cerebrovascular Disorders; Cholester

2001
Diet and drug synergism in treatment of hypercholesterolemia.
    Nutrition reviews, 1978, Volume: 36, Issue:1

    Topics: Adult; Cholesterol, Dietary; Fats, Unsaturated; Female; Humans; Hypercholesterolemia; Hyperlipidemia

1978
Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.
    Drugs, 1978, Volume: 15, Issue:6

    Topics: Animals; Arteriosclerosis; Clofibrate; Dogs; Humans; Hypercholesterolemia; Hyperlipidemias; Kinetics

1978
[Therapeutic orientation in the hyperlipidemias].
    Arquivos brasileiros de cardiologia, 1979, Volume: 33, Issue:3

    Topics: Cholestyramine Resin; Dextrothyroxine; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic

1979
Approaches to the management of hypercholesterolaemia.
    Journal of clinical pharmacy and therapeutics, 1992, Volume: 17, Issue:2

    Topics: Bezafibrate; Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperchol

1992
[Advance in drug treatment of primary and familial hypercholesterolemia].
    Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine, 1991, Volume: 11, Issue:5

    Topics: Animals; Cholestyramine Resin; Drugs, Chinese Herbal; Humans; Hypercholesterolemia; Hyperlipoprotein

1991
[Mechanisms of anti-atherogenic effect of probucol and the prospects of its clinical use].
    Kardiologiia, 1991, Volume: 31, Issue:6

    Topics: Arteriosclerosis; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Drug Evaluation; Humans; Hyperch

1991
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
    JAMA, 1990, Dec-19, Volume: 264, Issue:23

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit A

1990
Management of hyperlipidemia of kidney disease.
    Kidney international, 1990, Volume: 37, Issue:3

    Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem

1990
Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
    Drugs, 1989, Volume: 37, Issue:6

    Topics: Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Phenols; Probucol

1989
Probucol in long-term treatment of hypercholesterolemia.
    General pharmacology, 1988, Volume: 19, Issue:3

    Topics: Animals; Humans; Hypercholesterolemia; Phenols; Probucol; Time Factors

1988
The probucol experience: a review of the past and a look at the future.
    The American journal of cardiology, 1988, Jul-25, Volume: 62, Issue:3

    Topics: Animals; Antioxidants; Arteriosclerosis; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Hype

1988
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
    European heart journal, 1987, Volume: 8 Suppl E

    Topics: Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hype

1987
Treatment of hypercholesterolemia.
    Annual review of medicine, 1986, Volume: 37

    Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination;

1986
Mode of hypocholesterolemic action of probucol in animals and man.
    Artery, 1987, Volume: 14, Issue:2

    Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Humans; Hypercholestero

1987

Trials

45 trials available for probucol and Elevated Cholesterol

ArticleYear
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2014, Volume: 23, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug T

2014
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
    Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:1

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers

2006
Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
    Fukuoka igaku zasshi = Hukuoka acta medica, 2006, Volume: 97, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascul

2006
Low-dose colestipol plus probucol for hypercholesterolemia.
    The American journal of cardiology, 1984, Jun-01, Volume: 53, Issue:11

    Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Constipation; Diarrhea; Double-Blind Metho

1984
[Effect of probucol on blood lipids].
    Arquivos brasileiros de cardiologia, 1982, Volume: 39, Issue:1

    Topics: Aged; Cholesterol; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Male; Middle Aged

1982
Nine years of treatment with probucol.
    Artery, 1982, Volume: 10, Issue:1

    Topics: Arrhythmias, Cardiac; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Electrocardiograph

1982
[Action of probucol in the control of hypercholesterolemia].
    Arquivos brasileiros de cardiologia, 1980, Volume: 34, Issue:4

    Topics: Adult; Cholesterol; Clinical Trials as Topic; Diet; Female; Humans; Hypercholesterolemia; Male; Phen

1980
[A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)].
    La Nouvelle presse medicale, 1980, Oct-30, Volume: 9, Issue:40

    Topics: Adult; Cholesterol; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Humans; H

1980
The long-term effects of probucol on serum lipid levels.
    Archives of internal medicine, 1981, Volume: 141, Issue:11

    Topics: Cholesterol; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Humans; Hypercholes

1981
Safety and effectiveness of probucol as a cholesterol lowering agent.
    Artery, 1982, Volume: 10, Issue:1

    Topics: Adult; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Humans; Hypercholesterolemia; Myo

1982
[Behavior of high-density lipoproteins in drug lipid-lowering treatment].
    Schweizerische medizinische Wochenschrift, 1982, Jan-16, Volume: 112, Issue:3

    Topics: Adult; Apoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibric Acid; Colestipol; Humans;

1982
Probucol in hypercholesterolemia. A double blind study.
    Atherosclerosis, 1980, Volume: 36, Issue:2

    Topics: Adult; Aged; Apolipoproteins; Cholesterol; Double-Blind Method; Female; Humans; Hypercholesterolemia

1980
Usefulness of probucol in treating primary hypercholesterolemia.
    Canadian Medical Association journal, 1980, Oct-18, Volume: 123, Issue:8

    Topics: Adult; Aged; Cholesterol; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probucol

1980
High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.
    European journal of clinical pharmacology, 1995, Volume: 48, Issue:3-4

    Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Drug Combinations; Female; Humans; Hypercholesterolemia;

1995
Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
    Arteriosclerosis, thrombosis, and vascular biology, 1995, Volume: 15, Issue:8

    Topics: Apolipoprotein A-I; Arteriosclerosis; Cholesterol, HDL; Cholestyramine Resin; Female; Femoral Artery

1995
Probucol treatment decreases serum concentrations of diet-derived antioxidants.
    Arteriosclerosis, thrombosis, and vascular biology, 1995, Volume: 15, Issue:8

    Topics: Antioxidants; Cholestyramine Resin; Diet; Female; Humans; Hypercholesterolemia; Male; Middle Aged; P

1995
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
    The New England journal of medicine, 1995, Feb-23, Volume: 332, Issue:8

    Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease

1995
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
    The New England journal of medicine, 1995, Feb-23, Volume: 332, Issue:8

    Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease

1995
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
    The New England journal of medicine, 1995, Feb-23, Volume: 332, Issue:8

    Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease

1995
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
    The New England journal of medicine, 1995, Feb-23, Volume: 332, Issue:8

    Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease

1995
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
    The American journal of cardiology, 1994, Nov-01, Volume: 74, Issue:9

    Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Fem

1994
Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
    European journal of clinical pharmacology, 1993, Volume: 44, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Do

1993
The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).
    The American journal of cardiology, 1993, Feb-25, Volume: 71, Issue:6

    Topics: Aged; Antioxidants; Arteriosclerosis; Cholesterol; Dietary Fats; Double-Blind Method; Female; Humans

1993
The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
    Atherosclerosis, 1996, Sep-06, Volume: 125, Issue:2

    Topics: Adult; Angiography; Anticholesteremic Agents; Arteriosclerosis; Disease Progression; Female; Femoral

1996
High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet.
    Atherosclerosis, 1998, Volume: 138, Issue:1

    Topics: Aged; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol,

1998
Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
    Diabetes research and clinical practice, 1999, Volume: 43, Issue:2

    Topics: Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Body Mass Index; Cholesterol; Cholestero

1999
Effect of probucol on hypercholesterolemia in renal transplant patients.
    Kidney international. Supplement, 1999, Volume: 71

    Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Cholesterol, LDL

1999
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).
    Journal of the American College of Cardiology, 2002, Feb-20, Volume: 39, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Carotid Artery Diseases; Carotid Artery, C

2002
Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia.
    Clinical pharmacology and therapeutics, 1976, Volume: 20, Issue:6

    Topics: Cholesterol; Clinical Trials as Topic; Depression, Chemical; Drug Evaluation; Female; Humans; Hyperc

1976
Probucol (Lorelco) in treatment of hyperlipemia.
    JAMA, 1977, Dec-05, Volume: 238, Issue:23

    Topics: Cholesterol; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipidemias; Lipoproteins,

1977
Treatment of severe and mild hypercholesterolaemia with probucol and neomycin.
    Postgraduate medical journal, 1975, Volume: 51, Issue:8

    Topics: Clinical Trials as Topic; Feces; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lipoproteins, VLDL

1975
Effect of probucol in hyperlipidemic patients during two years of administration.
    American heart journal, 1978, Volume: 96, Issue:2

    Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Hyperlipid

1978
Probucol, a new cholesterol lowering drug.
    Journal of medicine, 1975, Volume: 6, Issue:5-6

    Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Humans; Hyperchole

1975
Treatment of severe and mild hypercholesterolaemia with probucol and neomycin..
    Postgraduate medical journal, 1975, Volume: 51, Issue:8

    Topics: Cholesterol; Clinical Trials as Topic; Humans; Hypercholesterolemia; Neomycin; Phenols; Probucol; Tr

1975
Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
    Arteriosclerosis and thrombosis : a journal of vascular biology, 1992, Volume: 12, Issue:3

    Topics: Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Lipid Peroxidation; Lipids; Lipoproteins; Li

1992
[Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
    Arquivos brasileiros de cardiologia, 1991, Volume: 57, Issue:3

    Topics: Analysis of Variance; Brazil; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Fe

1991
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
    The American journal of cardiology, 1990, Mar-20, Volume: 65, Issue:12

    Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-C

1990
Changes in atheroma volume estimated from digitized femoral arteriograms.
    Acta radiologica (Stockholm, Sweden : 1987), 1990, Volume: 31, Issue:3

    Topics: Algorithms; Angiography, Digital Subtraction; Arteriosclerosis; Double-Blind Method; Female; Femoral

1990
A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
    The American journal of cardiology, 1990, Sep-18, Volume: 66, Issue:8

    Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Evaluation; F

1990
Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
    The American journal of cardiology, 1989, Mar-15, Volume: 63, Issue:11

    Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-Co

1989
Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles.
    Atherosclerosis, 1988, Volume: 72, Issue:2-3

    Topics: Apolipoproteins; Clinical Trials as Topic; Genetic Carrier Screening; Humans; Hypercholesterolemia;

1988
Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
    The American journal of cardiology, 1988, Jul-25, Volume: 62, Issue:3

    Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Combined Modality Therapy; Drug Th

1988
[Probucol in patients with diabetes mellitus type II with hypercholesterolemia].
    Arquivos brasileiros de cardiologia, 1987, Volume: 48, Issue:2

    Topics: Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hyper

1987
Controlled studies of the efficacy and safety of combined probucol-colestipol therapy.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; Double-Blind Method; Drug

1986
Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1986, Volume: 8, Issue:6

    Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; Female; Human

1986
Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
    International journal of clinical pharmacology, therapy, and toxicology, 1986, Volume: 24, Issue:9

    Topics: Adult; Aged; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy,

1986
Probucol in the long-term treatment of hypercholesterolaemia.
    Current medical research and opinion, 1973, Volume: 1, Issue:6

    Topics: Adult; Anticholesteremic Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Drug Hypersensi

1973
Long-term oral administration of probucol (4,4'-(isopropylidenedithio) bis(2,6-di-t-butylphenol)) (DH-581) in the management of hypercholesterolemia.
    Journal of the American Geriatrics Society, 1974, Volume: 22, Issue:4

    Topics: Administration, Oral; Adult; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Clinical Trial

1974

Other Studies

106 other studies available for probucol and Elevated Cholesterol

ArticleYear
HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution.
    Atherosclerosis, 2018, Volume: 278

    Topics: Animals; Apolipoproteins E; Atherosclerosis; Bone Marrow; Bone Marrow Transplantation; Cholesterol,

2018
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
    Lipids in health and disease, 2013, Nov-04, Volume: 12

    Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol;

2013
Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.
    International journal of molecular medicine, 2014, Volume: 34, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Brain Injuries; Brain Ischemia; CD11b Antigen; Cerebr

2014
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
    Histology and histopathology, 2014, Volume: 29, Issue:12

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combinat

2014
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
    Lipids in health and disease, 2015, Jul-29, Volume: 14

    Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hy

2015
Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice.
    Arteriosclerosis, thrombosis, and vascular biology, 2016, Volume: 36, Issue:4

    Topics: Androstadienes; Animals; Anticholesteremic Agents; Aorta; Aortic Diseases; Apolipoprotein A-I; Apoli

2016
Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.
    Journal of atherosclerosis and thrombosis, 2008, Volume: 15, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cohort Studies; Disease-Free Surviva

2008
Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 338, Issue:2

    Topics: Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Drug Therapy, Combination; Hyperch

2011
In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish.
    The Journal of clinical investigation, 2011, Volume: 121, Issue:12

    Topics: Animals; Animals, Genetically Modified; Antibodies, Monoclonal; Anticholesteremic Agents; Blood Vess

2011
Does methylmercury-induced hypercholesterolemia play a causal role in its neurotoxicity and cardiovascular disease?
    Toxicological sciences : an official journal of the Society of Toxicology, 2012, Volume: 130, Issue:2

    Topics: Animals; Anticholesteremic Agents; Behavior, Animal; Biomarkers; Cardiovascular Diseases; Cerebellum

2012
Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein pe
    Bulletin of experimental biology and medicine, 2002, Volume: 134, Issue:1

    Topics: Antioxidants; Cholesterol; Cholesterol, LDL; Coenzymes; Double-Blind Method; Enzyme Inhibitors; Free

2002
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)].
    Nihon Jinzo Gakkai shi, 2002, Volume: 44, Issue:8

    Topics: Aged; Anticholesteremic Agents; Cyclosporine; Drug Interactions; Drug Monitoring; Drug Therapy, Comb

2002
Effects of probucol on renal function and urinary protein excretion in spontaneously hypercholesterolemic rats fed a normal or high cholesterol diet.
    Kidney & blood pressure research, 2004, Volume: 27, Issue:2

    Topics: Animals; Anticholesteremic Agents; Blood Pressure; Cholesterol, Dietary; Dose-Response Relationship,

2004
Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits.
    Journal of cardiovascular pharmacology, 2006, Volume: 47, Issue:1

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Body Weight; Gene Expressio

2006
[Effect of probucol and losartan on growth factors after balloon angioplasty in rabbits].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2006, Volume: 31, Issue:2

    Topics: Angioplasty, Balloon; Animals; Anticholesteremic Agents; Coronary Restenosis; Drug Therapy, Combinat

2006
Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.
    International journal of cardiology, 2007, Jan-31, Volume: 115, Issue:1

    Topics: Animals; Anticholesteremic Agents; CD36 Antigens; Cholesterol, HDL; Disease Models, Animal; Hepatocy

2007
Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia.
    American journal of physiology. Heart and circulatory physiology, 2006, Volume: 291, Issue:5

    Topics: Animals; Anticholesteremic Agents; Aorta; Elasticity; Enzyme Inhibitors; Hypercholesterolemia; Immun

2006
Effect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits.
    International journal of cardiology, 2008, Jan-11, Volume: 123, Issue:2

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Hypercholesterolemia; Male; Probucol; Rabbits; Thro

2008
Probucol with cholestyramine.
    Lancet (London, England), 1981, Jul-11, Volume: 2, Issue:8237

    Topics: Cholestyramine Resin; Drug Synergism; Humans; Hypercholesterolemia; Phenols; Probucol

1981
Lowered HDL cholesterol and incidence of ischaemic heart disease.
    Lancet (London, England), 1981, Aug-29, Volume: 2, Issue:8244

    Topics: Cholesterol; Cholesterol, HDL; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, HDL; Ph

1981
Probucol and the QT interval.
    Lancet (London, England), 1982, May-22, Volume: 1, Issue:8282

    Topics: Electrocardiography; Heart; Humans; Hypercholesterolemia; Phenols; Probucol

1982
Influence of probucol on cholesterol and lipoprotein metabolism in man.
    Journal of lipid research, 1984, Volume: 25, Issue:8

    Topics: Adult; Aged; Apolipoproteins; Bile; Cholesterol; Female; Humans; Hypercholesterolemia; Kinetics; Lip

1984
Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
    Atherosclerosis, 1981, Volume: 40, Issue:2

    Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Dose-Respon

1981
Clinical experience with probucol with special emphasis on mode of action and long-term treatment.
    Artery, 1982, Volume: 10, Issue:1

    Topics: Cholesterol; Coronary Disease; Electrocardiography; Heart Diseases; Humans; Hypercholesterolemia; Ph

1982
Experience with probucol in the treatment of hypercholesterolemia.
    Artery, 1982, Volume: 10, Issue:1

    Topics: Cholesterol; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Ag

1982
Correlative design of electrophoretic and ultracentrifugal investigation of metabolic effects of probucol.
    Artery, 1982, Volume: 10, Issue:2

    Topics: Blood Protein Electrophoresis; Coronary Disease; Diet; Electrophoresis, Agar Gel; Humans; Hyperchole

1982
Probucol: effects on the metabolism of low density and high density lipoproteins in moderate hypercholesterolaemia.
    Artery, 1982, Volume: 10, Issue:2

    Topics: Cholesterol; Humans; Hypercholesterolemia; Kinetics; Lipoproteins, HDL; Lipoproteins, LDL; Phenols;

1982
Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
    Artery, 1982, Volume: 10, Issue:2

    Topics: Adult; Aged; Apoproteins; Cholesterol; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperc

1982
The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
    Atherosclerosis, 1982, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diarrhea; Electrocardiogra

1982
[Comparative effect of probucol and clofibrate in patients with primary hypercholesterolemia].
    La Clinica terapeutica, 1982, Dec-15, Volume: 103, Issue:5

    Topics: Adult; Clofibrate; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle

1982
Synergistic effects of probucol and cholestyramine to lower serum cholesterol.
    Journal of clinical pharmacology, 1981, Volume: 21, Issue:1

    Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Dietary Fats; Drug Synergism; Drug Therapy, Combinat

1981
[Clinical assessment of probucol and its therapeutical effect on hypercholesterolaemia (author's transl)].
    Casopis lekaru ceskych, 1981, Jul-09, Volume: 120, Issue:27

    Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Humans; Hypercholesterolemia; Male; Midd

1981
Probucol and hypercholesterolaemia.
    British journal of clinical pharmacology, 1981, Volume: 11, Issue:5

    Topics: Adult; Aged; Bile; Cholesterol; Diet; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Male;

1981
Probucol: a weak hypocholesterolemic agent.
    Canadian Medical Association journal, 1981, Jul-15, Volume: 125, Issue:2

    Topics: Adult; Double-Blind Method; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probuc

1981
[Effects of probucol on plasma cholesterol and triglyceride levels].
    Arquivos brasileiros de cardiologia, 1981, Volume: 37, Issue:5

    Topics: Adult; Body Weight; Chemical Phenomena; Chemistry; Cholesterol; Hemodynamics; Humans; Hypercholester

1981
[Probucol in the treatment of hypercholesterolemia].
    Arquivos brasileiros de cardiologia, 1981, Volume: 37, Issue:1

    Topics: Adult; Aged; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probucol; Triglycerid

1981
[Probucol: mechanism of action (author's transl)].
    La Nouvelle presse medicale, 1980, Oct-30, Volume: 9, Issue:40

    Topics: Animals; Bile; Cholesterol; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Liver; Mice; Phenols

1980
[Plasma levels of probucol in man after single and repeated oral doses (author's transl)].
    La Nouvelle presse medicale, 1980, Oct-30, Volume: 9, Issue:40

    Topics: Administration, Oral; Half-Life; Humans; Hypercholesterolemia; Phenols; Probucol; Time Factors

1980
Probucol treatment and thyroid function tests.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1980, Nov-22, Volume: 58, Issue:21

    Topics: Adult; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probucol; Thyroid Hormones

1980
Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation.
    Arteriosclerosis, thrombosis, and vascular biology, 1995, Volume: 15, Issue:10

    Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins B; Arteries; Arteriosclerosis; Cell Divisi

1995
Effect of dietary antioxidants on the susceptibility to hepatic microsomal lipid peroxidation in the rat.
    Annals of nutrition & metabolism, 1995, Volume: 39, Issue:2

    Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Cholesterol; Diet; Fatty Acids; Food, Fortified; Hy

1995
Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters.
    Arteriosclerosis, thrombosis, and vascular biology, 1995, Volume: 15, Issue:3

    Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Corn Oil; Cricetinae; Diet, Atherogenic; Dose-Respon

1995
Probucol reduces renal injury in the ExHC rat.
    Nephron, 1994, Volume: 67, Issue:4

    Topics: Animals; Cholesterol; Electrophoresis; Food, Fortified; Hypercholesterolemia; Kidney Glomerulus; Lip

1994
Probucol-induced QT prolongation and syncope.
    Japanese circulation journal, 1994, Volume: 58, Issue:5

    Topics: Atrial Fibrillation; Diltiazem; Electrocardiography; Female; Humans; Hypercholesterolemia; Long QT S

1994
Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
    The Journal of clinical investigation, 1994, Volume: 94, Issue:1

    Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, Dietary; Hypercholesterolemia; Lipoproteins

1994
Ameliorative effect of dietary probucol on polychlorinated biphenyls-induced hypercholesterolemia and lipid peroxidation in the rat.
    Life sciences, 1994, Volume: 54, Issue:14

    Topics: Animals; Cholesterol; Cholesterol, HDL; Diet; Hypercholesterolemia; Lipid Peroxidation; Liver; Male;

1994
Enhancement of aortic cholesterol deposition by dietary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents.
    Journal of pharmacological and toxicological methods, 1993, Volume: 30, Issue:3

    Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Desmo

1993
Factors related to QT interval prolongation during probucol treatment.
    European journal of clinical pharmacology, 1993, Volume: 45, Issue:1

    Topics: Electrocardiography; Female; Humans; Hypercholesterolemia; Long QT Syndrome; Male; Middle Aged; Prob

1993
Choice of cholesterol-lowering drugs.
    The Medical letter on drugs and therapeutics, 1993, Mar-05, Volume: 35, Issue:891

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Huma

1993
Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia.
    Clinical biochemistry, 1993, Volume: 26, Issue:2

    Topics: Apolipoprotein A-I; Apolipoprotein A-II; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Lip

1993
Marked decrease in serum HDL cholesterol levels by combined probucol-pravastatin treatment in hypercholesterolemic NIDDM patients.
    Diabetes care, 1993, Volume: 16, Issue:5

    Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Comb

1993
Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence.
    Journal of lipid research, 1993, Volume: 34, Issue:5

    Topics: Adipose Tissue; Animals; Apolipoproteins E; Carrier Proteins; Cholesterol Ester Transfer Proteins; C

1993
Long-term administration of probucol and QTc interval prolongation.
    Artery, 1993, Volume: 20, Issue:2

    Topics: Aged; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Probucol; Time F

1993
Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes.
    Life sciences, 1996, Volume: 58, Issue:6

    Topics: Animals; Anticholesteremic Agents; Aorta; Catalase; Cholesterol, Dietary; Dose-Response Relationship

1996
Action of probucol in arteries from normal and hypercholesterolaemic rabbits.
    British journal of pharmacology, 1996, Volume: 118, Issue:7

    Topics: Animals; Anticholesteremic Agents; Arteries; Arteriosclerosis; Calcium; Calcium Radioisotopes; Chole

1996
Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats.
    Life sciences, 1997, Volume: 60, Issue:3

    Topics: Administration, Oral; Animals; Anticholesteremic Agents; Biological Availability; Cholesterol; Cross

1997
Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
    Kidney international, 1997, Volume: 51, Issue:4

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol, Dietary; Diet; Glomerulosclerosis, Foc

1997
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
    Chest, 1997, Volume: 112, Issue:4

    Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem

1997
Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
    Journal of cardiovascular pharmacology, 1997, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Ca

1997
Effect of probucol on serum lipoprotein and apoprotein profiles in renal transplant patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1998, Volume: 31, Issue:2

    Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Fatty Acids, Nonesterified; Female; H

1998
Silymarin inhibits the development of diet-induced hypercholesterolemia in rats.
    Planta medica, 1998, Volume: 64, Issue:2

    Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Female; Glut

1998
Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits.
    The American journal of the medical sciences, 1998, Volume: 315, Issue:4

    Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol, Dietary; Endothelium, Vascular; Hyperch

1998
Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography.
    Journal of cardiology, 1998, Volume: 31, Issue:4

    Topics: Anticholesteremic Agents; Blood Component Removal; Coronary Angiography; Coronary Artery Disease; Fo

1998
Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits.
    Atherosclerosis, 1998, Volume: 141, Issue:1

    Topics: Adrenergic beta-Antagonists; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidant

1998
Involvement of MCP-1 and M-CSF in glomerular foam cell formation in ExHC rats.
    Kidney international. Supplement, 1999, Volume: 71

    Topics: Animals; Anticholesteremic Agents; Chemokine CCL2; Cholesterol, Dietary; Foam Cells; Hypercholestero

1999
Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits.
    Journal of lipid research, 1999, Volume: 40, Issue:11

    Topics: Animals; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Copper;

1999
Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.
    Lipids, 2001, Volume: 36, Issue:5

    Topics: Animals; Becaplermin; Blood Flow Velocity; Carotid Arteries; Carotid Artery Thrombosis; Cells, Cultu

2001
Alpha-tocopherol and probucol reduce autoantibody titer to MDA-LDL in hypercholesterolemic rabbits.
    Free radical biology & medicine, 2001, Sep-15, Volume: 31, Issue:6

    Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Autoanti

2001
Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis.
    Circulation, 2002, May-14, Volume: 105, Issue:19

    Topics: Actins; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Choleste

2002
Drug management of hypercholesterolemia.
    American heart journal, 1979, Volume: 97, Issue:3

    Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Humans; Hypercholesterolemia; Nicotin

1979
Use of diet and probucol.
    Archives of internal medicine, 1979, Volume: 139, Issue:9

    Topics: Child; Cholestyramine Resin; Female; Humans; Hypercholesterolemia; Phenols; Probucol

1979
[Hypolipidemic effects of DH581 during prolonged administration (author's transl)].
    Giornale italiano di cardiologia, 1976, Volume: 6, Issue:3

    Topics: Adolescent; Adult; Aged; Body Weight; Cholesterol; Drug Evaluation; Female; Humans; Hypercholesterol

1976
Contribution of the endothelium to intimal thickening in normocholesterolemic and hypercholesterolemic rabbits.
    Arteriosclerosis and thrombosis : a journal of vascular biology, 1992, Volume: 12, Issue:10

    Topics: Animals; Arteriosclerosis; Cell Division; Disease Models, Animal; Hypercholesterolemia; Immunohistoc

1992
Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits.
    Experimental and molecular pathology, 1992, Volume: 57, Issue:1

    Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Ascorbic Acid; Blood Vessels; Cholesterol; Cholester

1992
Time-dependent change in the effect of probucol in subjects with elevated cholesterol.
    European journal of clinical pharmacology, 1992, Volume: 43, Issue:3

    Topics: Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Male;

1992
Probucol, incorporated into LDL particles in vivo, inhibits generation of lipid peroxides more effectively than endogenous antioxidants alone.
    Clinical biochemistry, 1992, Volume: 25, Issue:5

    Topics: Antioxidants; Cholesterol; Humans; Hypercholesterolemia; Lipid Peroxides; Lipoproteins, LDL; Male; P

1992
Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1992, Volume: 24, Issue:6

    Topics: Aged; Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Fe

1992
[Separation of high density lipoprotein (HDL) using anti-apo A-I, apo A-II immuno-affinity chromatography to evaluate the effects of probucol].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1991, Volume: 28, Issue:6

    Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Chromatography, Affinity; Drug Evaluation; Fem

1991
Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia.
    The American journal of cardiology, 1991, Oct-01, Volume: 68, Issue:9

    Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Female; Humans; Hy

1991
Role of cholesteryl ester transfer protein in reverse cholesterol transport.
    Clinical cardiology, 1991, Volume: 14, Issue:2 Suppl 1

    Topics: Apolipoproteins E; Biological Transport; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer P

1991
Clinical and therapeutic use of probucol.
    European journal of clinical pharmacology, 1991, Volume: 40 Suppl 1

    Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Humans; Hypercholesterolemia; Platelet Aggregation; Plate

1991
[Modified LDL and its physiological significance].
    Nihon rinsho. Japanese journal of clinical medicine, 1990, Volume: 48, Issue:11

    Topics: Animals; Arteriosclerosis; Foam Cells; Humans; Hypercholesterolemia; Lipoproteins, LDL; Probucol; Re

1990
Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer.
    Atherosclerosis, 1990, Volume: 84, Issue:2-3

    Topics: Adult; Aged; Cholesterol Esters; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Lipids; Lip

1990
Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
    Atherosclerosis, 1990, Volume: 82, Issue:1-2

    Topics: Aged; Cells, Cultured; Cholesterol; Cholestyramine Resin; Fatty Acids; Female; Food, Formulated; Hum

1990
Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.
    Atherosclerosis, 1990, Volume: 82, Issue:1-2

    Topics: Adult; Aged; Cholesterol, LDL; Colestipol; Female; Follow-Up Studies; Humans; Hypercholesterolemia;

1990
In vitro activity of probucol on cholesteryl ester transport.
    Biochimica et biophysica acta, 1990, Aug-06, Volume: 1045, Issue:3

    Topics: Biological Transport; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Hum

1990
Probucol in hypercholesterolemia.
    DICP : the annals of pharmacotherapy, 1989, Volume: 23, Issue:11

    Topics: Humans; Hypercholesterolemia; Phenols; Probucol

1989
Lack of effect of probucol on serum lipoprotein(a) levels.
    Atherosclerosis, 1989, Volume: 79, Issue:2-3

    Topics: Adult; Aged; Apolipoproteins A; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Pr

1989
[Recent trend in the research of hyperlipidemia in Japan. Influence of defective metabolism of low-density lipoprotein on atherosclerosis].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1989, Volume: 78, Issue:10

    Topics: Arteriosclerosis; Foam Cells; Humans; Hypercholesterolemia; Lipoproteins, LDL; Probucol

1989
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1989, Mar-10, Volume: 109, Issue:7-8

    Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Norway; Probuc

1989
Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats.
    Atherosclerosis, 1989, Volume: 78, Issue:2-3

    Topics: Animals; Arteriosclerosis; Cell Adhesion; Cholesterol; Endothelium, Vascular; Hypercholesterolemia;

1989
Probucol versus eptastatin in hypercholesterolaemic diabetics.
    Lancet (London, England), 1986, Sep-27, Volume: 2, Issue:8509

    Topics: Cholesterol, HDL; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Mal

1986
Current and new therapy for hypercholesterolemia.
    The Journal of the American Osteopathic Association, 1988, Volume: 88, Issue:7

    Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin;

1988
Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol.
    The Journal of family practice, 1988, Volume: 26, Issue:2

    Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Combined Modality Therapy; Drug Therapy, Combination; Fe

1988
[How do changes in the plasma concentration of HDL induced by probucol operate?].
    Medicina clinica, 1988, Apr-02, Volume: 90, Issue:13

    Topics: Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Phenols; Probucol

1988
A symposium: Second International Conference on Hypercholesterolemia--examining new data on probucol after a decade of use.
    The American journal of cardiology, 1988, Jul-25, Volume: 62, Issue:3

    Topics: Animals; Humans; Hypercholesterolemia; Phenols; Probucol

1988
Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
    The American journal of cardiology, 1988, Jul-25, Volume: 62, Issue:3

    Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Corneal

1988
The effects of probucol on QT/QS2 relation and systolic time intervals.
    International journal of cardiology, 1988, Volume: 19, Issue:3

    Topics: Adult; Arrhythmias, Cardiac; Cardiac Output; Cholesterol; Electrocardiography; Female; Humans; Hyper

1988
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
    Archives of internal medicine, 1988, Volume: 148, Issue:1

    Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet

1988
Current pharmacologic treatment of elevated serum cholesterol.
    Circulation, 1987, Volume: 76, Issue:3

    Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co

1987
Lipoprotein fractions and receptors: a role for probucol?
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Anticholesteremic Agents; Biological Transport; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL;

1986
Lovastatin: cholesterol-lowering agent.
    American family physician, 1987, Volume: 36, Issue:6

    Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Humans; Hypercholesterolemia;

1987
A symposium: new developments in the treatment of hypercholesterolemia--probucol. Introduction.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, LDL; Phenols; Probuc

1986
A symposium: New developments in the treatment of hypercholesterolemia--probucol. December 7, 1985, New York, New York.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Phenols; Probucol

1986
Discrepancies between the outcome of animal and human studies on the mode of action of probucol.
    Atherosclerosis, 1986, Volume: 61, Issue:3

    Topics: Animals; Apolipoproteins B; Aryl Hydrocarbon Hydroxylases; Bile; Cholesterol, HDL; Cholesterol, LDL;

1986
Probucol inhibits oxidative modification of low density lipoprotein.
    The Journal of clinical investigation, 1986, Volume: 77, Issue:2

    Topics: Animals; Cells, Cultured; Copper; Endothelium; Female; Humans; Hypercholesterolemia; Lipid Peroxides

1986